Аннотация:
Taking matrix metalloproteinase MMP-2 as an example, we demonstrate that the rational design of oligopeptide-based inhibitors by molecular modeling should involve both a study of interactions in the active sites of the target enzyme and the conformational dynamics of the oligopeptide in solution.